TransThera Sciences

• Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)

  Phase 2, Recruiting, 182 people, Oct 13, 2026

• A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma

  Phase 2, Not yet recruiting, 188 people, Oct 2, 2026

• NCT07498478

  Phase 2, Recruiting, 94 people, Mar 27, 2026

• NCT07328919

  Phase 3, Not yet recruiting, 138 people, Jan 9, 2026

• NCT06457919

  Collaborator, Phase 1/2, Recruiting, 50 people, Jun 13, 2024

Sources: clinicaltrials.gov